GlassScriptPhysician profile
Jennifer Madu
NPI 1952705501
$2,176.97
in general payments reported to CMS, 2019-2025
19 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $1,051 · 2023: $577 · 2024: $256 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $330.15 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $275.88 | 2021-2025 | Rexulti, Abilify Mycite |
| Alkermes, INC. | $248.51 | 2022-2023 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $245.53 | 2021-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $214.62 | 2022 | |
| Bausch Health US, LLC | $140.60 | 2021-2023 | Aplenzin |
| Abbvie INC. | $135.96 | 2021-2024 | |
| Lundbeck LLC | $92.47 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $85.96 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $82.27 | 2021-2022 | |
| Axsome Therapeutics, INC. | $79.35 | 2022-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $68.27 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.24 | 2022-2023 | Austedo |
| Harmony Biosciences LLC | $28.01 | 2023 | Wakix |
| Corium, LLC | $27.08 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $24.30 | 2022 | |
| Biogen, INC. | $23.04 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.57 | 2025 | Rejoyn |
| Idorsia Pharmaceuticals US INC | $15.16 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Madu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.